CASP9 and amyotrophic lateral sclerosis: Celecoxib (PUBCHEM_CID: 2662) was prioritized for molecular docking due to its association with PDK1 (AD, ALS) and CASP9 (PD), its well-documented anti-inflammatory properties, and its potential to modulate mitochondrial metabolism and apoptosis pathways, making it a promising multi-target candidate for neurological disorders.